Literature DB >> 2845790

Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

M L Warnock1, A Stoloff, A Thor.   

Abstract

The immunohistochemical reactivity of 38 mesotheliomas and 44 adeno-carcinomas or large cell carcinomas of the lung with monoclonal antibodies (MAb) B72.3 and Leu M1 was compared with their reactivity with the routine histochemic stains periodic acid-Schiff with diastase digestion (PAS-D) and alcian blue +/- hyaluronidase. Both MAbs reacted selectively with carcinomas when a positive test was set at greater than or equal to 10% reactive tumor cells. However, MAb B72.3 reacted with significantly more of the carcinomas (86%, chi-square test, P less than 0.01) and bound to a greater percentage of tumor cells (47 +/- 28%; mean +/- SD, t-test, P less than 0.001) than Leu M1 (57% and 25 +/- 28%, respectively). The similar reactivities of surgically resected tumor specimens and post mortem tissues with both antibodies confirmed antigen stability and suggested broad clinical utility. PAS-D stained 61% of the carcinomas. Using the markers for carcinomas (PAS-D, B72.3, and Leu M1), the tumors were classified into the correct group in 80 of 82 (98%) cases (95% confidence level: greater than 92% accuracy). The alcian blue stain was useful to confirm a diagnosis of dimorphic or epithelial mesothelioma (48% were positive).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845790      PMCID: PMC1880639     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

Review 1.  Asbestos and mesothelioma: a review.

Authors:  M Kannerstein; J Churg; W T McCaughey
Journal:  Pathol Annu       Date:  1978

2.  A critique of the criteria for the diagnosis of diffuse malignant mesothelioma.

Authors:  M Kannerstein; W T McCaughey; J Churg; I J Selikoff
Journal:  Mt Sinai J Med       Date:  1977 Jul-Aug

3.  Distinction between cells in serous effusions using a panel of antibodies.

Authors:  A F Lauritzen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Immunohistochemical staining in malignant mesotheliomas.

Authors:  J G Strickler; B G Herndier; R V Rouse
Journal:  Am J Clin Pathol       Date:  1987-11       Impact factor: 2.493

5.  Histochemistry in the diagnosis of malignant mesothelioma.

Authors:  M Kannerstein; J Churg; D Magner
Journal:  Ann Clin Lab Sci       Date:  1973 May-Jun       Impact factor: 1.256

6.  A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells.

Authors:  S N Hanjan; J F Kearney; M D Cooper
Journal:  Clin Immunol Immunopathol       Date:  1982-05

7.  Rod and cone psychophysics and electroretinography: methods for comparison in retinal degenerations.

Authors:  K Yagasaki; S G Jacobson; P P Apáthy; R W Knighton
Journal:  Doc Ophthalmol       Date:  1988-06       Impact factor: 2.379

8.  Mesotheliomas: a light- and electron-microscopical study concerning histogenetic relationships between the epithelial and the mesenchymal variants.

Authors:  J W Bolen; D Thorning
Journal:  Am J Surg Pathol       Date:  1980-10       Impact factor: 6.394

9.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells.

Authors:  D Colcher; P H Hand; M Nuti; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.

Authors:  C N Otis; D Carter; S Cole; H Battifora
Journal:  Am J Surg Pathol       Date:  1987-06       Impact factor: 6.394

View more
  15 in total

1.  Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.

Authors:  D Jordon; J Jagirdar; M Kaneko
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

2.  Novel method for detection of glycogen in cells.

Authors:  Alexander V Skurat; Dyann M Segvich; Anna A DePaoli-Roach; Peter J Roach
Journal:  Glycobiology       Date:  2017-05-01       Impact factor: 4.313

Review 3.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

Review 4.  Update on special techniques in routine cytopathology.

Authors:  I D Buley
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

Review 5.  Diagnostic tests in pleural effusion--an update.

Authors:  N Berkman; M R Kramer
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

6.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.

Authors:  U Latza; G Niedobitek; R Schwarting; H Nekarda; H Stein
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

7.  Diagnostic tools for differentiating pleural mesothelioma from lung adenocarcinoma in paraffin embedded tissue. II. Design of an expert system and its application to the diagnosis of mesothelioma.

Authors:  H Moch; M Oberholzer; H Christen; M Buser; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.

Authors:  C L Collins; N G Ordonez; R Schaefer; C D Cook; S S Xie; J Granger; P L Hsu; L Fink; S M Hsu
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

9.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.